# INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

Study · id `cardio:ct-nct06965504` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06965504](<https://clinicaltrials.gov/study/NCT06965504>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06965504

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT06965504. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-02 (actual); primary completion 2028-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT06965504, source copy `cardio:ctgov-nct06965504-2026-11-12`, retrieved 2026-11-18)
- Started: 2026-10-02 (actual) (ClinicalTrials.gov record NCT06965504, source copy `cardio:ctgov-nct06965504-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-12-01 (anticipated) (ClinicalTrials.gov record NCT06965504, source copy `cardio:ctgov-nct06965504-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-06-01 (anticipated) (ClinicalTrials.gov record NCT06965504, source copy `cardio:ctgov-nct06965504-2026-11-12`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT06965504, source copy `cardio:ctgov-nct06965504-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06965504-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
- Acronym: INTeGRATE
- Condition: Heart Failure
- Condition: Cardiogenic Shock
- Condition: Reduced Ejection Fraction Heart Failure
- Intervention (Device): Impella 5.5 SmartAssist
- Lead sponsor: Abiomed Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Johnson & Johnson
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Abiomed Inc. (`cardio:org-abiomed-inc`)
- Registry lists this organization as a collaborator: Johnson & Johnson (`cardio:org-johnson-johnson`)

## Provenance

Content hash: c421629109befaf1fccdf0caa41339bc6a2e8709bb559282135ab17aee882bcc
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
